Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary ...
The Phase 2b randomized, crossover study (Clinicaltrials.gov identifier NCT02503345) will evaluate the safety, tolerability and efficacy of three different doses of ALLN-177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria.
Business Wire (press release) - Tue, 04 Aug 2015 05:22

Allena begins Phase IIb trial of ALLN-177 to treat secondary hyperoxaluria
The randomized, crossover study Phase IIb trial is designed to evaluate the safety, tolerability and efficacy of three different doses of ALLN-177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria. The company said that ...
Pharmaceutical Business Review - Wed, 05 Aug 2015 23:44



EMA Grants Orphan Drug Designation to DCR-PH1, Dicerna's Investigational ...
... developer of RNA interference (RNAi) therapeutics, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to DCR-PH1, the company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1).
MarketWatch - Thu, 06 Aug 2015 13:03

Dicerna Announces Second Quarter 2015 Financial and Operational Results
Business Wire (press release) - Thu, 06 Aug 2015 13:03

Leerink Swann Lowers Dicerna Pharmaceuticals Price Target to $30.00 (DRNA)
Dakota Financial News - Fri, 07 Aug 2015 10:15

Analysts Give $26.33 Consensus Target Price to Dicerna Pharmaceuticals (NASDAQ ...
In the rare disease field, the Company is developing a treatment, DCR-PH1, for the rare and serious inherited disorder Primary Hyperoxaluria 1 (PH1) by targeting the liver metabolic enzyme glycolate oxidase. The Company also has discovery and early ...
Dakota Financial News - Sun, 16 Aug 2015 06:52

Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and ...
Present pre-clinical data for ALN-GO1 in development for the treatment of Primary Hyperoxaluria Type 1 (PH1) at the 48th Annual Scientific Meeting of the European Society of Paediatric Nephrology (ESPN), being held September 3 – 5, 2015 in Brussels, ...
Business Wire (press release) - Thu, 06 Aug 2015 12:52

Allena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the ...
Hyperoxaluria is excessive urinary excretion of oxalate, a condition resulting from either hyperabsorption of dietary oxalate or the overproduction of oxalate in the body due to one of several known genetic defects. Hyperoxaluria, if left untreated ...
Business Wire (press release) - Wed, 18 Mar 2015 05:22

Analysts Give Consensus Rating of "Strong Buy" to Dicerna Pharmaceuticals ...
In the rare disease field, the Company is developing a treatment, DCR-PH1, for the rare and serious inherited disorder Primary Hyperoxaluria 1 (PH1) by targeting the liver metabolic enzyme glycolate oxidase. The Company also has discovery and early ...
Dakota Financial News - Thu, 13 Aug 2015 05:11

Moving Stocks: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), salesforce.com ...
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to DCR-PH1, the company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1). PH1 is a ...
Stock Transcript - Mon, 24 Aug 2015 01:03


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014